早期非小细胞肺癌立体定向消融放疗的分次实施时间安排对疗效的影响:一项基于人群的分析
该基于人群的研究纳入404例接受48 Gy分4次立体定向消融放疗的I期非小细胞肺癌患者,按隔日、每日含周末、连续每日不含周末三种时间安排分组,发现≥2级毒性、局部失败和总生存在各组间均无统计学显著差异;作者认为选择方案时可考虑患者便利性和资源优化。
要点
- 48 Gy分4次SABR的隔日、每日含周末、连续每日三种时间安排间≥2级毒性和局部失败无显著差异。
- 三组24个月局部失败率分别为7.5%、9.5%、11.0%(P=0.60),未记录4级或5级毒性。
- 中位总生存三组分别为47.5、52.7、49.0个月,每日含周末和连续每日方案与总生存无关。
核心结论
- 该基于人群的研究表明,I期非小细胞肺癌患者接受48 Gy分4次肺SABR时,隔日、每日含周末和连续每日不含周末三种时间安排在≥2级毒性率、局部失败和总生存方面均无统计学显著差异。
- 作者认为选择肺SABR治疗实施时间安排时可考虑患者便利性和资源优化。
研究设计与样本
- 基于人群分析,2019年1月至2022年6月从省级癌症登记处提取接受48 Gy分4次SABR的治疗记录,按实施安排分为隔日、每日含周末和连续每日不含周末三组。
- 共404例符合研究标准的患者,隔日组190例、每日含周末组111例、连续每日不含周末组103例。
- 毒性事件采用美国国家癌症研究所不良事件通用术语标准5.0版记录,总生存采用Kaplan-Meier法计算,局部失败采用以死亡为竞争风险的累积发生率法计算。
- 采用Cox回归分析和Fine-Gray模型分别评估与总生存和局部失败相关的变量。
主要发现
- 中位随访时间29.5个月(IQR 19.2-38.4个月)。
- 急性与晚期≥2级毒性的粗率在各组间无统计学差异,未记录4级或5级毒性。
- 24个月局部失败率在隔日组为7.5%(95%CI 3.7-11.3)、每日含周末组为9.5%(95%CI 3.9-15.1)、连续每日不含周末组为11.0%(95%CI 4.9-17.2),P=0.60。
- 每日含周末和连续每日不含周末方案与局部失败无关。
- 中位总生存在隔日组为47.5个月(95%CI 39.26-55.74)、每日含周末组为52.7个月(95%CI 34.7-70.7)、连续每日不含周末组为49.0个月(95%CI 31.6-66.4),各组间无显著差异;每日含周末和连续每日不含周末方案与总生存无关。
临床怎么用
- 作者认为选择肺SABR治疗实施时间安排时可考虑患者便利性和资源优化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal SABR treatment delivery schedule in stage I non-small cell lung cancer (NSCLC) remains unclear. This population-based study investigated grade ≥2 toxicity rates, local failure (LF), and overall survival (OS) in patients treated with 48 Gy in 4 fractions scheduled every other day versus daily with weekends and consecutive daily without weekends. METHODS AND MATERIALS: Between January 2019 and June 2022, treatment records using 48 Gy in 4 fractions were extracted from a provincial cancer registry and grouped by delivery as every other day, daily with weekends, or consecutive daily without weekends. Toxicity events were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The Kaplan-Meier method was used to compute OS and LF was calculated using cumulative incidence methods with death as a competing risk. Cox regression analyses and Fine-Gray modeling was used to assess for variables associated with OS and LF, respectively. RESULTS: Of 404 patients meeting study criteria, 190, 111, and 103 received SABR every other day, daily with weekends, and consecutive daily without weekends, respectively. More patients receiving SABR daily with weekends were medically inoperable and more patients receiving SABR consecutive daily without weekends had tumors abutting the chest wall. Median follow-up time was 29.5 months (IQR, 19.2-38.4 months). Overall toxicity was low, with crude rates of acute and late grade ≥2 toxicity not being statistically different among the groups. No grade 4 or 5 toxicities were recorded. LF rates at 24 months were not different at 7.5% (95% CI, 3.7-11.3), 9.5% (95% CI, 3.9-15.1), and 11.0% (95% CI, 4.9-17.2) for the every other day, daily with weekends, and consecutive daily without weekends groups, respectively (P = .60). Schedules of daily with weekends and consecutive daily without weekends were not associated with LF. Similarly, no significant differences in median OS were found among the every other day, daily with weekends, and consecutive daily without weekends groups at 47.5 months (95% CI, 39.26-55.74), 52.7 months (95% CI, 34.7-70.7), and 49.0 months (95% CI, 31.6-66.4), respectively. Schedules of daily with weekends and consecutive daily without weekends were not associated with OS. CONCLUSIONS: This population-based study demonstrated no statistically significant differences in grade ≥2 toxicity rates, LF, and OS for patients with stage I NSCLC treated with lung SABR using 48 Gy in 4 fractions delivered every other day, daily with weekends, and consecutive daily without weekends. Patient convenience and optimization of resources may be considered when choosing a lung SABR treatment delivery schedule.
引用
- Abrina JP, Baker S, Cruz-Lim EM, et al. Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis. Pract Radiat Oncol. 2024. PMID: 39303778. doi:10.1016/j.prro.2024.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。